07-26-04

a plus sign (+) inside this box  $\Pi$ Approved for use through 09/30/2000. OMB 0651-0031 Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number. 09/903,925 **Application Number** July 11, 2001 **TRANSMITTAL** Filing Date **FORM** Avi Ashkenazi, et al. First Named Inventor (to be used for all correspondence after initial filing) 1647 Group/Art Unit **Examiner Name** Fozia M. HAMUD Total Number of Pages in This Submission 66 pgs. Attorney Docket Number 39780-1618P2C49 ENCLOSURES (check all that apply) **Assignment Papers** After Allowance Communication Fee Transmittal Form (for an Application) to Group Appeal Communication to Board Drawing(s) Fee Attached of Appeals and Interferences Appeal Communication to Group Amendment / Response Licensing-related Papers (Appeal Notice, Brief, Reply Brief) After Final Petition Routing Slip (PTO/SB/69) Proprietary Information and Accompanying Petition Version with Markings Showing Petition to Convert to a Status Letter Changes **Provisional Application** Affidavits/declaration(s) Power of Attorney, Revocation Additional Enclosure(s) M Change of Correspondence Address (please identify below): Extension of Time Request stamped return postcard; Terminal Disclaimer PTO Form 1449; Information Disclosure Statement copies of 7 cited reference **Small Entity Statement** Certified Copy of Priority Request for Refund Document(s) Response to Missing Parts/ Remarks Incomplete Application **AUTHORIZATION TO CHARGE DEPOSIT ACCOUNT 08-1641 FOR ANY FEES** Response to Missing DUE IN CONNECTION WITH THIS PAPER. Parts under 37 CFR 1.52 or 1.53 SIGNATURE OF APPLICANT, ATTORNEY OR AGENT Firm Daphne Reddy, Reg. No. 53,507 HELLER EHRMAN WHITE & McAULIFFE LLP Individual name Signature Daphne Date Customer Number: 09157/35489 July 23, 2004 CERTIFICATE OF MAILING I hereby certify that this correspondence is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. §1.10 on the date indicated below and addressed to: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on this date: July 23, 2004. Typed or printed name Sandra Puljic Signature

Date

July 23, 2004

CERTIFICATE OF EXPRESS MAILING

Thereby certify that this correspondence is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. §1.10 on the date indicated below and addressed to: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on this date: July 23, 2004

Express Mail Label EL 993 692 181 US

Typed or printed name Sandra Puljic

Signature Sundra Puljic Date July 23, 2004

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:

Avi Ashkenazi, et al.

Docket No.:

39780-1618P2C49

Serial No.:

09/903,925

Group Art Unit:

1647

Filing Date:

July 11, 2001

Examiner:

Fozia M. HAMUD

For:

SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC

ACIDS ENCODING THE SAME

07/28/2004 SDIRETAI 00000015 081641

09903925

01 FC:1806

180.00 DA

## INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. §1.97

Mail Stop: Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

Listed on an attached Form PTO-1449 is information known to applicant(s). Each reference listed has been cited in a related patent application, US Serial No. 09/903,640 (claiming PRO 343 polypeptide); Our Ref. No. 39780-1618P2C48 and/or US Serial No. 09/909,320 (claiming PRO 343 nucleic acid); Our Ref. No. 39780-1618P2C80. A copy of each reference is provided herewith. Applicants submit these documents to ensure that all references are of record and considered in all related applications. Applicants respectfully request the Examiner to acknowledge consideration of the currently submitted references by initialing and returning form PTO-1449 in accordance with MPEP §609.

This statement is not intended to represent that a search has been made or that the information cited in the statement is, or is considered to be, material to patentability as defined in §1.56.

	This sta	tement	qualifies under 37 C.F.R. §1.97,	ifies under 37 C.F.R. §1.97, subsection (b) because (check all that apply):							
		(1) It is being filed within 3 months of the application filing date and is other to continued prosecution application under § 1.53(d)  OR									
		(2)	It is being filed within 3 months OR	of entry of a national stage							
		(3)		date of the first Office Action on the merits							
		(4)		ng of a first Office Action after the filing of a on under § 1.114.							
	37 C.F.R. $\S1.97(c)$ . If this statement is being filed after the latest of: (1) three months beyond filing date of a national application; (2) three months beyond the date of entry of the national stage as set forth in $\S1.491$ in an international application; or (3) the mailing date of a first Of action on the merits, but before the mailing date of the earlier of a final office action under $\S1$ or a notice of allowance under $\S1.311$ , then:										
		a certification as specified in §1.97(e) is provided below; or									
	$\boxtimes$		f \$180.00 as set forth in \$1.17(p) ment of other papers filed togeth	is authorized below, enclosed, or included with er with this statement.							
	37 C.F.R. §1.97(d). If this statement is being filed after the mailing date of the earlier of a final office action under §1.113 or a notice of allowance under §1.311, but before payment of the issue fee, then:										
	A.	a certification as specified in §1.97(e) is completed below; and									
	B.	a petition under 37 C.F.R. §1.97(d) requesting consideration of this statement is submitted herewith; and									
	C.	a fee of \$180.00 as set forth in §1.17(i)(1) is authorized below, enclosed, or included with the payment of other papers filed together with this statement.									
$\boxtimes$	of \$180	Fee Authorization. The Commissioner is hereby authorized to charge the above-referenced fees of \$180.00 and charge any additional fees or credit any overpayment associated with this communication to Deposit Account No. <u>08-1641</u> ( <u>Docket No. 39780-1618P2C49</u> ).									
				Respectfully submitted,							
Dated:	July 23, 2004			By: Daphne Reddy							
				Daphne Réddy Reg. No. 53,507							

HELLER EHRMAN WHITE & MCAULIFFE LLP

Customer No. 09157/35489 275 Middlefield Road

Menlo Park, CA 94025-3506 Telephone: (650) 324-7000/Facsimile: (650) 324-0638

PEAC	MATION DISCLOSTATEMENT  PTO-1449	OSURE	ATTY. DOCKET NO.: 39780-1618P2C49 APPLICANT: Avi Ashke FILING DATE: July 11, 2	SERIAL NO.: 09/903,925 GROUP: 1647					
PROTE TRADE		<b>U.</b> :	S. PATENT DOCUMENTS						
EXAMINER'S INITIALS	PATENT NO. DATE		NAME CLASS		SUBCLASS	FILIN	FILING DATE		
<del></del>									
	<u></u>								
						TRANS	SLATION		
						YES	NO		
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)									
	Atwood, Teresa. K., "The Babel of Bioinformatics", Science, Vol. 290, 2000, pp 471-473								
	Berendsen, Herman J.C., "A Glimpse of the Holy Grail?", Science, Vol. 282, 1998, pp 642-643								
	Galperin, Michael Y., et al, "Who's your neighbor?, New Computational approaches for functional genomics", Nature Biotechnology, Vol. 18, 2000, pp 609-613								
	Pennica et al, "WISP genes are members of the connective tissue growth factor family that are up-regulated in Wnt-1-transformed cells and aberrantly expressed in human colon tumors", Proc. Natl. Acad. Sci. USA, Vol. 95, December 1998, pp 14717-14722								
	Accession No. AC003965, Direct Submission, Submitted: December 31, 1997, Ricke, D. O. et al.								
	Accession No. AB010779, Direct Submission, Submitted: January 27, 1998, Yamaguchi et al.								
	Accession No. AAA61698, WO 200031211-A1, Pub Date: June 2, 2000, Fuso Pharm. Ind. Ltd.								
				····					
EXAMINER			DATE CONSIDERED						

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.